Good Safety Profile Reported for Biweekly Schedule of Capecitabine and Irinotecan

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 8
Volume 14
Issue 8

MADRID, SPAIN-Capecitabine(Xeloda) plus irinotecan (Camptosar),in a biweekly schedule as firstlinetreatment of locally advanced ormetastatic colorectal cancer, is an activeschedule with a manageable tox

MADRID, SPAIN-Capecitabine(Xeloda) plus irinotecan (Camptosar),in a biweekly schedule as firstlinetreatment of locally advanced ormetastatic colorectal cancer, is an activeschedule with a manageable toxicityprofile, even in patients olderthan 65 years. This conclusion andsupporting results from a phase II trialwere reported by Pilar Garcia-Alfonso,MD, of Hospital Gregorio Maranonin Madrid (abstract 3540).Dr. Garcia-Alfonso said that thebiweekly schedule of capecitabine/irinotecan (XELIRI) was less toxic thanthe standard 3-weekly XELIRI regimen.All 45 patients enrolled in thetrial were evaluable for safety. Grade3/4 toxicities were uncommon (Table1). The most common grade 3/4 toxicityamong patients ≤ 65 years wasalopecia, occurring in 5 patients (3%)younger than age 65 but in no patientsolder than 65. The most common adverseevents among these older patientswere asthenia (nine patients[4%]) and diarrhea (seven patients[3%]).50% Response RateThe overall response rate amongthe 38 patients evaluable for efficacywas 50% (95% confidence interval[CI]: 33%-67%). This total included 3patients with complete responses and16 patients with partial responses. Thetumor-growth control rate (responserate plus stable disease rate) was 87%(CI 95%: 72%-96%). Dr. Garcia-Alfonsosaid that a total of 50 patientswill be enrolled to evaluate time toprogression.

The 2-week treatment cycle consistedof 175 mg/m2 of irinotecan administeredon day 1 as a 90-minuteinfusion and 1,000 mg/m2 of oralcapecitabine twice daily on days 2 to 8.For patients older than age 65, theirinotecan dose was reduced to 140mg/m2 and the capecitabine dose, to750 mg/m2 twice daily. The medianrelative dose intensity was 94% forcapecitabine and nearly 100% foririnotecan.The median age of the patients was67 years (range, 42-80 years), with 25patients (56%) older than age 65. EasternCooperative Oncology Group(ECOG) performance status was 0 to 1in 93% of patients. Primary tumorsites were the colon (22 patients[51%]), rectum (21 patients [47%]),or both (1 patient [2%]). The mediannumber of metastatic lesions was two,and the most common sites were theliver (56%) and the lungs (23%).Previous treatment, such as surgery(73%), adjuvant chemotherapy(44%), and radiotherapy (20%), wasallowed if completed ≥ 6 months beforeenrollment.

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Related Content